Arcus Biosciences Inc (Arcus Biosciences) operates as a clinical-stage biopharmaceutical company focused on creating innovative cancer immunotherapies by leveraging underexploited biological opportunities. Its product pipeline includes AB928, a selective dual antagonist of the adenosine receptors known as A2aR and A2bR in combination with anti-PD-1 antibody (AB122) and chemotherapy is used for the treatment of metastatic triple-negative breast cancer or ovarian cancer and advanced malignancies; AB122, an anti-PD-1 antibody targeting cancer; AB154, an anti-TIGIT antibody; and AB680, a CD73 inhibitor against solid tumors. Arcus Biosciences is headquartered in Hayward, California, the US.
Arcus Biosciences Inc premium industry data and analytics
Products and Services
Products |
---|
Pipeline |
Domvanalimab : Non-Small Cell Lung Cancer |
AB308: Advanced Solid and Hematologic Malignancies |
XYZ |
XYZ |
XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
Year | Event | Description |
---|---|---|
2024 | Stake Sale | In January, the company sold an additional 13% stake to Gilead Sciences Inc. for US$320 million. |
2023 | Contracts/Agreements | In December, the company and Exelixis entered into a clinical trial collaboration for STELLAR-009. |
2023 | Contracts/Agreements | In May, the company and Gilead Sciences expanded their research collaboration to include therapies for the treatment of inflammatory diseases. |
Competitor Comparison
Key Parameters | Arcus Biosciences Inc | Merck & Co Inc | Pfizer Inc | Novartis AG | AstraZeneca Plc |
---|---|---|---|---|---|
Headquarters | United States of America | United States of America | United States of America | Switzerland | United Kingdom |
City | Hayward | Kenilworth | New York | Basel | Cambridge |
State/Province | California | New Jersey | New York | - | England |
No. of Employees | 577 | 72,000 | 88,000 | 76,057 | 89,900 |
Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
Name | Position | Board | Since | Age |
---|---|---|---|---|
Terry Rosen | Chairman; Chief Executive Officer | Executive Board | 2017 | 64 |
Jennifer Jarrett | Chief Operating Officer; Director | Executive Board | 2020 | 52 |
Juan Carlos Jaen | Director; President | Executive Board | 2015 | 65 |
Bob Goeltz | Chief Financial Officer | Senior Management | 2020 | - |
Dimitry Nuyten, M.D., Ph.D | Chief Medical Officer | Senior Management | 2022 | 47 |
Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Access more premium companies when you subscribe to Explorer